Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis C, Chronic Adenocarcinoma Blood-Borne Infections Carcinoma Carcinoma, Hepatocellular Chronic Disease Communicable Diseases Digestive System Diseases Digestive System Neoplasms Disease Attributes Flaviviridae Infections Hepatitis Hepatitis C Hepatitis, Chronic Hepatitis, Viral, Human Infections Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Pathologic Processes Pathological Conditions, Signs and Symptoms RNA Virus Infections Virus Diseases

Age range

25 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Gastroenterology and Hepatology, Kyoto University Hospital, Kyoto, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of Hepatocellular carcinoma due to Chronic Hepatitis C Virus Infection.
Must be treated with curative treatment for primary tumor using either surgical resection or radiofrequency ablation therapy

Exclusion criteria

No recurrence of hepatocellular carcinoma 3 months after the primary treatment
Renal dysfunction

Treatment and study plan

interferon-alfa-2b and ribavirin

Drug

Interferon, pnce per week plus daily ribavirin

Primary outcomes

Incidence of adverse effect of interferon

Time frame: During the treatment period

Sponsors and collaborators

Lead sponsor

Kyoto University

Other

Registry information

Official study title

Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma

Important dates

Study start: 2006
Primary completion: 2012
Study completion: 2013
First posted: Sep 13, 2006
Registry last updated: Sep 2, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed